首页> 美国卫生研究院文献>Archives of Rheumatology >Immunoglobulin G4-Related Disease Presented as Recurrent Otitis Media and Mixed Hearing Loss Treated With Cyclophosphamide and Rituximab: A Case Report
【2h】

Immunoglobulin G4-Related Disease Presented as Recurrent Otitis Media and Mixed Hearing Loss Treated With Cyclophosphamide and Rituximab: A Case Report

机译:免疫球蛋白G4相关疾病表现为复发性中耳炎和环磷酰胺和利妥昔单抗治疗的混合性听力损失:一例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Immunoglobulin G4-related disease (IgG4-RD) is a systemic autoimmune disease; however, it rarely presents as recurrent otitis media and mixed hearing loss. In this article, we present a 43-year-old male patient who presented with recurrent otitis media and mixed hearing loss that is the 12th case of IgG4-RD with middle and inner ear involvement. We also report the clinical response of cyclophosphamide and rituximab therapy in IgG4- RD. These two drugs have never been used to treat otologic symptoms, but were used to treat other organs affected by IgG4-RD. One year later, the patient underwent mastoidectomy of the right ear and the pathological reports revealed IgG4-related disease. A rheumatologist administered immunosuppressive therapy comprising cyclophosphamide and rituximab. After therapy, patient's right-sided mixed hearing loss partially improved. We recorded all pure tone audiometry data to evaluate the clinical course and treatment effect. Finally, we concluded that pathological confirmation and further immunosuppressive therapy should be considered in a timely manner to prevent hearing impairment. We recommend cyclophosphamide and rituximab for the treatment of diseases involving the middle and inner ear.
机译:免疫球蛋白G4相关疾病(IgG4-RD)是一种全身性自身免疫性疾病;然而,它很少表现为复发性中耳炎和混合性听力损失。在本文中,我们介绍了一名43岁的男性患者,该患者患有中耳炎反复发作和混合性听力下降,这是中耳和内耳受累的IgG4-RD的第12例。我们还报告了IgG4-RD中环磷酰胺和利妥昔单抗治疗的临床反应。这两种药物从未用于治疗耳科症状,但曾用于治疗受IgG4-RD影响的其他器官。一年后,该患者接受了右耳的乳突切除术,病理报告显示与IgG4相关的疾病。由风湿病学家进行的免疫抑制治疗包括环磷酰胺和利妥昔单抗。治疗后,患者右侧混合性听力损失得到部分改善。我们记录了所有纯音测听数据,以评估临床过程和治疗效果。最后,我们得出结论,应及时考虑病理证实和进一步的免疫抑制治疗,以防止听力障碍。我们建议使用环磷酰胺和利妥昔单抗治疗涉及中耳和内耳的疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号